Artwork

Innhold levert av CEimpact. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CEimpact eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Paxlovid in COVID-19 Vaccinated patients

26:21
 
Del
 

Manage episode 418005992 series 2931422
Innhold levert av CEimpact. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CEimpact eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Join us as we explore new trial data examing Paxlovid's effectiveness in high-risk, vaccinated patients.
The GameChanger
Significantly high risk patients are still at risk from active Covid-19 infection. A new trial looks at Paxlovid use in high-risk, vaccincated patients.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
New England Journal of Medicine Article
Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss EPIC SR study findings.
2. Describe benefits of Paxlovid for specific patient groups based on trial data.
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-172-H01-P
Initial release date: 05/13/2024
Expiration date: 05/13/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

Kapitler

1. Paxlovid in COVID-19 Vaccinated patients (00:00:00)

2. COVID Treatment Update and Study Results (00:00:08)

3. Effectiveness of Paxlovid for COVID-19 (00:12:46)

305 episoder

Artwork
iconDel
 
Manage episode 418005992 series 2931422
Innhold levert av CEimpact. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CEimpact eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Join us as we explore new trial data examing Paxlovid's effectiveness in high-risk, vaccinated patients.
The GameChanger
Significantly high risk patients are still at risk from active Covid-19 infection. A new trial looks at Paxlovid use in high-risk, vaccincated patients.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
New England Journal of Medicine Article
Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss EPIC SR study findings.
2. Describe benefits of Paxlovid for specific patient groups based on trial data.
0.05 CEU/0.5 Hr
UAN: 0107-0000-24-172-H01-P
Initial release date: 05/13/2024
Expiration date: 05/13/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

  continue reading

Kapitler

1. Paxlovid in COVID-19 Vaccinated patients (00:00:00)

2. COVID Treatment Update and Study Results (00:00:08)

3. Effectiveness of Paxlovid for COVID-19 (00:12:46)

305 episoder

Semua episode

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett